

openheart Copper chelation in patients with hypertrophic cardiomyopathy

Anna Reid,¹ Christopher Miller,^{1,2} John Peter Farrant ,^{1,2} Rahul Polturi,³ David Clark,¹ Simon Ray,^{1,2} Garth Cooper,^{2,4} Matthias Schmitt¹

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/openhrt-2021-001803>).

To cite: Reid A, Miller C, Farrant JP, *et al*. Copper chelation in patients with hypertrophic cardiomyopathy. *Open Heart* 2022;**9**:e001803. doi:10.1136/openhrt-2021-001803

Received 5 August 2021
Accepted 15 November 2021



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Cardiovascular Division, Northwest Heart Centre, Manchester University NHS Foundation Trust, Manchester, UK

²Division of Cardiovascular Sciences, The University of Manchester, Manchester, UK

³ACALM Study Unit, Aston University, Birmingham, UK

⁴Division of Cardiovascular Sciences, Centre for Advanced Discovery and Experimental Therapeutics (CADET), The University of Manchester, Manchester, UK

Correspondence to
Dr John Peter Farrant; john.farrant@mft.nhs.uk

ABSTRACT

Background Disturbances of copper (Cu) homeostasis can lead to hypertrophic cardiac phenotypes (eg, Wilson's disease). We previously identified abnormal Cu homeostasis in patients with hypertrophic cardiomyopathy (HCM) and, therefore, hypothesised that Cu²⁺-selective chelation with trientine dihydrochloride may slow or reverse disease progression in HCM. The aim of this study was, therefore to explore the clinical efficacy, safety and tolerability of trientine in HCM.

Methods In this medicines and healthcare products regulatory agency (MHRA) registered open-label pilot study, we treated 20 HCM patients with trientine for 6 months. Patients underwent a comprehensive assessment schedule including separate cardiac magnetic resonance imaging (CMR) and CMR ³¹P-spectroscopy at baseline and end of therapy. Predefined end points included changes in left ventricular mass (LVM), markers of LV fibrosis, markers of LV performance and myocardial energetics. Ten matched patients with HCM were studied as controls.

Results Trientine treatment was safe and tolerated. Trientine caused a substantial increase in urinary copper excretion (0.42±0.2 vs 2.02±1.0, p=0.001) without affecting serum copper concentrations. Treatment was associated with significant improvements in total atrial strain and global longitudinal LV strain using both Echo and CMR. LVM decreased significantly in the treatment arm compared with the control group (−4.2 g v 1.8 g, p=0.03). A strong trend towards an absolute decrease in LVM was observed in the treatment group (p=0.06). These changes were associated with a significant change in total myocardial volume driven by a significant reduction in extracellular matrix (ECM) volume (43.83±18.42 mL vs 41.49±16.89 mL, p=0.04) as opposed to pure cellular mass reduction and occurred against a background of significant ECM volume increase in the control group (44.59±16.50 mL vs 47.48±19.30 mL, p=0.02). A non-significant 10% increase in myocardial phosphocreatine/adenosine triphosphate (PCr/ATP) ratio with trientine therapy (1.27±0.44 vs 1.4±0.39) was noted.

Conclusions Cu²⁺-selective chelation with trientine in a controlled environment is safe and a potential future therapeutic target. A phase 2b trial is now underway.

INTRODUCTION

Hypertrophic Cardiomyopathy (HCM), the most common monogenetic inherited cardiac disorder affecting 1 in every 500 of

Key questions

What is already known about this subject?

► Disturbances of copper homeostasis can lead to hypertrophic cardiac phenotypes, and it has previously identified that patients with hypertrophic cardiomyopathy (HCM) can have abnormal copper homeostasis.

What does this study add?

► The use of the copper chelator Trientine in patients with HCM is safe and well tolerated.
► Treatment was associated with improvements in many pathophysiological imaging biomarkers of HCM.

How might this impact clinical practice?

► This study has led to the 'randomised, double-blind, placebo-controlled, phase 2 evaluation of the efficacy and mechanism of trientine in patients with hypertrophic cardiomyopathy (TEMPEST)' clinical trial for further evaluation of this drug in the HCM population.

the population.¹ It is characterised by left ventricular (LV) hypertrophy (LVH). Histologically, HCM displays myocyte enlargement and disarray, increased interstitial and replacement fibrosis and dysplastic intramyocardial arterioles.

Despite advances in diagnosis and risk stratification, there remains no licensed disease-modifying treatment for HCM. Indeed, since HCM was first described, there have been less than 50 pharmacological studies, enrolling less than 2500 patients. In 2010, a National Institutes of Health working group identified a 'critical need for future research considerations directed toward basic and translational studies to identify putative targets for intervention. When viable targets are identified, clinical studies should be undertaken to determine if novel (or currently available) drug, or other therapies, can target these pathways of HCM disease expression and, improve on the natural history of patients with this disease'.²

Copper (Cu) is an essential cofactor for a variety of metabolic functions and while

regulation of systemic Cu metabolism is critical to human health,³ free Cu ions are extremely redox-active and, thus, potentially toxic.⁴ Defective Cu metabolism is said to impair cardiovascular health in at least two known settings; chronic Cu deficiency and defective intracellular Cu transport to mitochondrial cytochrome-C oxidase. Cu excess is seen in Wilson's disease and Chagas Cardiomyopathy,^{5,6} with both conditions being characterised by LVH, and indeed both mimicking HCM. Cu deficiency, on the other hand, has been linked to the development of various phenotypes of cardiomyopathy.⁷ Simplistically, one can summarise that disturbances of Cu homeostasis can lead to both dilated and hypertrophic forms of cardiomyopathy and that Cu chelation, in the absence of Cu deficiency, is may be able to reverse LVH and organ fibrosis via a Cu-dependent mechanism that reduces oxidative stress as demonstrated by us previously, both in animal and human studies.⁸

In a prospective observational cohort study of 20 HCM patients and 18 matched healthy volunteers, we found that HCM was associated with significantly elevated serum copper and caeruloplasmin.⁹

Trientine dihydrochloride is a copper-chelating agent licensed for Wilson disease. In a randomised placebo-controlled trial in patients with type II diabetes and LVH, trientine was associated with a significant reduction in LV mass (LVM) without changes in blood pressure (BP) or glucose.¹⁰ Cumulative urine copper excretion was independently associated with the observed decrease in LVM.

In the present study, we aimed to explore the safety, tolerability and efficacy of trientine dihydrochloride in patients with HCM.

METHODS

Study design

This was an open-label single-site pilot study including 20 patients with HCM. Written, informed consent was obtained from all participants.

Ten additional age and gender-matched patients with HCM were recruited to a parallel 'natural-history-control' observational study to allow comparison of baseline and end-point data (ref: 14/NW/0060). Recruitment criteria were identical to those for the pilot study.

Patient Selection

Inclusion criteria were as follows: (1) age ≥ 18 years, (2) a clinical diagnosis of HCM in line with the 2011 American College of Cardiology Foundation/American Heart Association consensus document, (3) LV ejection fraction $\geq 50\%$. Exclusion criteria are shown listed in the supplementary data (online supplemental table S1).

Intervention

Patients received trientine dihydrochloride 300 mg capsules at an initial dose of 300 mg two times per day, which was increased after 1 week to 600 mg two times per day if tolerated. Trientine was given for 6 months. Dose reductions were permitted in patients experiencing an

adverse event. Patients were asked to return remaining capsules at each visit to assess compliance.

Study outline visit schedule

Online supplemental figure 1 in the supplementary data shows a study design flowchart. It was initially intended to schedule study visits at approximately 1 month, 2-month and 3-month intervals, however, for ease of dispensing of bottles of trientine (one bottle=25 days supply) and to limit time away from refrigeration, patients were followed up at 25-day multiples, without affecting study safety or integrity. No formal assessment of quality of life was performed.

Patients in the observational control study underwent cardiac magnetic resonance imaging (CMR) and phosphorous cardiac magnetic resonance spectroscopy (³¹P-CMRS) baseline and again at 6 months to match the trientine pilot study.

Cardiac magnetic resonance

Patients underwent CMR scanning at 1.5T (Avanto, Siemens AG, Erlangen, Germany). A dedicated and standardised HCM-CMR protocol was used in all. Steady-state free precession (SSFP) cine images were acquired in standard long-axis views. A stack of short-axis slices covered the left ventricle (LV), and left atrium (LA) for volumetric analysis. LV mass and volumetric analysis were performed using dedicated offline software (CMR Tools, Cardiovascular Imaging Solutions, London, UK).

Pre-contrast T1 mapping (Siemens MOLLI WIPP 448) was performed in the basal and mid short axis slices (chosen from the SSFP cines stack), four-chamber and three-chamber view. T2 mapping and T2* sequences were performed at the mid ventricular level. A circumferential region of interest was drawn to include the mid-LV wall, with care taken to avoid blood pool. Minimum, maximum and mean T1 values were noted. A blood sample was taken prior to CMR to measure serum haematocrit. Standard late gadolinium enhancement imaging (including phase-sensitive inversion-recovery) was performed at least 10 min after the final dose of contrast agent (Dotarem 0.15 mmol/kg). Postcontrast T1 mapping was performed exactly 15 min after contrast administration. Extracellular volume (ECV) fraction, total myocardial volume, extracellular matrix (ECM) volume and cellular volume were calculated as previously described.¹¹

Atrial and ventricular deformation/strain analysis were performed using commercially available feature tracking technology (TOMTEC Diogenes).

³¹P-cardiac MR spectroscopy

³¹P-CMRS is an advanced MRI technique, which allows for the non-invasive, in vivo assessment of components of energy handling within myocardium. All patients underwent 3T ³¹P-CMRS at visits 2 and 6 (Achieva TX, Phillips, Best, Netherlands) using a dedicated, commercially available ³¹P-transmit and receive coil (14 cm). Scans were performed with the patient lying prone. The protocol

included acquiring survey images taken to assess the position of the mid interventricular septum relative to the centre of the coil, and the patient was repositioned as required to ensure minimal distance between the centre coil and isocentre of the magnet. Two ^{31}P -spectra were acquired using a standard manufacturer supplied ^{31}P -spectroscopy sequence. Spectra were summed and analysed on jMRUI software, with the PCr peak used as the reference peak. Quantification was first performed using the AMARES (Advanced Method for Accurate, Robust and Efficient Spectral fitting) fitting programme, in which the peaks and line widths of 2,3-diphosphoglycerate, PCr, and α , β and γ -ATP were automatically determined, and corrected for blood contamination as previously described.¹² Area under the peak was used to determine the concentrations of metabolites, and myocardial phosphocreatine/adenosine triphosphate (PCr/ATP) ratio was subsequently calculated.

Echocardiography

Transthoracic echocardiography was performed on all patients using a GE vivid-9 machine. All measurements were made according to the American Society of Echocardiography guidelines and averaged over three cardiac cycles, during breath hold. Analysis was performed offline using customised software (EchoPac v113, GE Vingmed Ultrasound, Horten, Norway). Deformation analyses, that is, atrial and ventricular strain measurements, were based on speckle tracking technology.

All CMR, ^{31}P CMRS and echocardiography analysis were performed by a Society of CMR and British Society of Echocardiography accredited operator blinded to patient data.

Cardiopulmonary exercise testing

Patients underwent symptom-limited (graded according to modified Borg scale) respiratory gas-exchange treadmill cardiopulmonary exercise testing. Tests were carried out using a modified Bruce protocol and the target respiratory exchange ratio (RER) was >1.1 for all studies. All tests were performed on the same system supervised by the same physician and analysed in a blinded fashion by a single experienced chief physiologist.

Adverse events

Adverse events assessed by the study investigators were recorded and followed up until resolution.

Outcome measures

Outcome measures were predefined as change in: (1) LVM, (2) markers of myocardial fibrosis (ie, native T1 and ECV), (3) LV myocardial deformation, (4) left atrial (LA) function, (5), myocardial energetics (PCr/ATP ratio), (6) exercise capacity.

Statistical analysis

Prespecified end points informing power calculation were change in LVM and PCr/ATP ratio after 6 months of treatment. Pilot work in patients with diabetes had

revealed a mean reduction in LVM of $5\text{g}/\text{m}^2$,¹² with interobserver variability in our group of $10\text{g}/\text{m}^2$. Using this data, 20 patients treated provided an 80% power to detect changes in LVM/body surface area (BSA) of $4.6\text{g}/\text{m}^2$ or more (using a paired t test with estimated SD of differences of $7\text{g}/\text{m}^2$) and changes of a PCr/ATP ratio of 0.36 or more (using a paired t test with estimated SD of differences of 0.55).

Power was also calculated for 15 patients, to allow for a 25% drop out rate (based on Conway *et al*¹²). The study then had 80% power to detect changes in LVM/BSA within the trientine group of $5.4\text{g}/\text{m}^2$ or more (using a paired t test with estimated SD of differences of $7\text{g}/\text{m}^2$).

Change in LVM and PCr/ATP ratio was used to inform power calculations. In the previously mentioned placebo controlled trial in diabetes, 6 months of treatment with trientine was associated with a within-group decrease in LVM indexed to body surface area (LVMI) of $5.0\pm 7.2\text{g}/\text{m}^2$.¹² Based on this data, 20 patients were required to provide 80% power for detecting a minimum difference in LVMI of $4.6\text{g}/\text{m}^2$ from baseline following 6 months of treatment, assuming an SD of $7\text{g}/\text{m}^2$ (5% significance level, two sided). Twenty patients would also provide 80% power for detecting a minimum difference in PCr/ATP ratio of 0.36, assuming an SD of 0.55 (5% significance level, two sided).

Analysis was performed using SPSS V.23.0 (SPSS, Chicago, Illinois, USA). Data are presented as mean \pm SD. Differences between groups were analysed using the paired or unpaired Student's t test, where appropriate. Statistical significance was defined as two-tailed p values <0.05 .

RESULTS

Study population

Twenty-five patients consented to the pilot study of trientine but five were excluded prior to starting trientine: two patients were newly diagnosed with diabetes mellitus; one patient was found to have a large pleural effusion; one patient was found to be iron deficient and one patient had abnormal liver function tests.

Of the remaining 20 patients, 15 patients completed the study, with two requiring dose reduction to 600 mg per day for the final 2 months of treatment, owing to gastrointestinal side effects. Four patients did not complete the study due to adverse effects and one patient withdrew due to a change in personal circumstance. Of the 10 patients who were recruited to the observational control group, one declined to return for follow-up and one declined the follow-up ^{31}P -CMRS. Both patients cited scan intolerability as the reason. Baseline patient characteristics are given in table 1.

Safety of trientine

Adverse events and their frequency are listed in the online supplemental tables S3, S4. There were four serious adverse events requiring hospitalisation: appendicitis

Table 1 Baseline patient characteristics

	Intervention group	Control group	P value*
Age (years)	55.5±8.4	54.7±13.3	0.86
Male	15	7	
Body surface area (m ²)	2.06±0.25	1.94±0.24	0.24
Systolic blood pressure (mm Hg)	130±15	137±13	0.24
Diastolic blood pressure (mm Hg)	81±12	75±15	0.28
Heart rate	66.5±16.3	65.1±11.5	0.81
PCr/ATP ratio	1.27±0.44	1.51±0.82	0.36
NYHA	14	7	
NYHA II	6	3	
EF (%)	69.0±6.8	69.8±8.3	0.79
Mass/BSA (g/m ²)	73.5±20.0	79.8±18.6	0.43

*An expanded version of this table is available in the online supplemental table S2. BSA, body surface area; EF, ejection fraction; NYHA, New York Heart association classification; PCr/ATP, myocardial phosphocreatine/adenosine triphosphate.

after 1 week of treatment; palpitations with previous similar admissions; a recurrence of adhesive capsulitis requiring admission for analgesia; wrist sprain following a fall. None was judged to be related to trientine.

Trientine has been associated with iron deficiency, sideroblastic anaemia and leucopenia. There was no significant change in serum iron (20.1±4.0 vs 18.9±5.8 µmol/L, p=0.4), haemoglobin (145±13 vs 143±13 g/L, p=0.4) or total white cell count (6.9±1.3 vs 7.0±1.6 × 10⁹/L, p=0.7) after 6 months of treatment. In addition, no clinically relevant change in renal or hepatic biochemistry or magnesium was observed.

Efficacy of trientine

Biochemistry and haemodynamic data

There was no change in serum copper or zinc after 6 months of trientine. There was a small but statistically significant increase in serum caeruloplasmin.

Compliance with 24-hour urinary copper collection was poor, particularly at the end of study visit (visit 6). Analysis was, therefore, conducted using data collected at visit 5 (150 days of treatment). Urinary copper increased significantly from baseline to visit 5 (0.42±0.2 vs 2.02±1.0 µmol/L/24 hours, p=0.001). Patients could continue in the study despite poor compliance with the 24-hour urine collections as change in urinary copper was not a primary outcome measure.

There were no clinically relevant changes in BP, heart rate or body surface area with trientine (table 2).

LVM and volumetrics

Six months of trientine was associated with a strong trend towards a decrease in LVM. Indeed, in comparison to the observational control group, LVM decreased significantly (−4.1±8.0 g vs 2.7±4.4 g, p=0.03) (see online supplemental

Table 2 Laboratory data

	Baseline	Follow-up*	P value*
<i>Laboratory data</i>			
Haemoglobin (g/L)	145.5±13.3	143.2±12.5	0.40
eGFR (mL/min/1.73 m ²)	82.7±8.6	84.5±7.2	0.30
Alkaline phosphatase (IU/L)	73.0±19.8	78.6±19.1	0.03
ALT (IU/L)	20.5±6.4	23.6±5.0	0.07
Magnesium (mmol/L)	0.87±0.08	0.81±0.12	0.14
Serum copper (µmol/L)	16.5±2.3	16.6±2.7	0.83
Serum caeruloplasmin (g/L)	0.23±0.03	0.24±0.03	0.04
<i>Haemodynamics</i>			
Systolic BP (mm Hg)	131±15	125±15	0.21
Diastolic BP (mm Hg)	83±14	74±7	0.06
Heart rate (bpm)	57.5±10.0	58.8±9.2	0.59

*An expanded version of this table is available in the online supplemental table S5. ALT, alanine transaminase; BP, blood pressure; eGFR, estimate glomerular filtration rate.

figure 2 in the supplementary data). No change was observed in LV volumetrics (table 3).

An expanded version of this table is available in the supplementary data.

CMR tissue characterisation

Trientine treatment resulted in a reduction in native T1 (1060±47 ms vs 1049±42 ms) and ECV fraction (30.0%±4.5% vs 29.5±4.0%), approaching statistical significance (p=0.06 for both, online supplemental figure 3). By contrast, there was a significant increase in ECV fraction in the control arm (29.0%±5.1% vs 30.6±6.3%, p=0.045) over the 6/12 study period. When determining compartmental myocardial changes based on these imaging parameters, trientine treatment was associated with a significant reduction in ECV, which occurred against a backdrop of a significant increase in ECM in the 'natural history' control group (see online supplemental figure 3 in the supplementary data).

There was a significant reduction in circumferential T2* (35.6±4.1 ms vs 34.3±3.6 ms, p<0.01), a change not seen in the control group (33.8±3.3 ms vs 33.0±3.9 ms, p=0.58). No difference in myocardial T2 was seen in either group.

Left ventricular deformation

There was significant improvement in global longitudinal strain, assessed both using feature tracking cardiac magnetic resonance imaging (FT-CMR) (−18.3±3.4 vs −19.4±3.4, p=0.03) and speckle-tracking echocardiography (−16.6±4.3 vs −18.9±4.4, p=0.01). Septal S' velocity also significantly increased (6.4±1.5 cm/s vs 7.8±2.2 cm/s, p=0.04). By contrast, the control group displayed a significant reduction in FT-CMR derived global longitudinal strain (−20.5±5.9 vs −19.2±5.1, p=0.01). No significant change was seen in circumferential strain in either group.

Table 3 Cardiac MRI and echographic data at baseline and after 6 months of treatment with trientine

	Baseline	Follow-up	P value
Cardiac MRI: left ventricle			
LVEDV (mL)	171±36	169±38	0.57
LVESV (mL)	54±20	52±20	0.41
SV (mL)	117±22	117±23	0.98
EF (%)	69±7	70±6	0.55
LVM (g)	152±54	147±55	0.06
Native septal T1 (ms)	1060±47	1049±42	0.06
ECV fraction (%)	30.0±4.5	29.5±4.0	0.06
Total myocardial volume (mL)	145±52	140±53	0.05
ECM volume (mL)	44±18	42±17	0.04
Cellular volume (mL)	101±36	99±37	0.11
Global longitudinal strain (%)	-18.3±3.4	-19.4±3.4	0.03
PCr/ATP ratio	1.27±0.44	1.4±0.39	0.46
Cardiac MRI: left atrium			
LAESV (mL)	75.8±43.6	65.8±40.9	0.04
LAEDV (mL)	124.4±51.3	114.6±47.3	0.18
Total EF (%)	41.3±8.3	45.5±12.2	0.07
LA expansion index	0.73±0.22	0.94±0.54	0.09
Total strain (%)	20.0±3.9	21.5±5.0	0.04
Peak systolic strain rate (-1)	0.75±13	0.83±0.19	0.11
Echocardiographic data			
E/A ratio	1.11±0.67	1.10±0.50	0.84
Mean S' velocity (cm/s)	6.9±2.5	8.1±1.9	0.03
Mean E' velocity (cm/s)	6.8±3.4	7.0±2.5	0.71
Mean A' velocity (cm/s)	7.4±3.1	8.4±2.7	0.11
Mitral deceleration time (ms)	295±79	265±47	0.11

ECV fraction was calculated as $ECV = (1 - \text{haematocrit}) \times \lambda$, where λ is the partition coefficient. Total myocardial volume was $LV \text{ mass} / 1.05$. The total extracellular volume (ECM) was calculated with the formula $ECM = ECV \times LVM / 1.05$, while the cellular volume was calculated as $\text{cellular volume (mL)} = \text{total myocardial volume} - \text{ECM volume}$.

An expanded version of this table is available in the online supplemental tables S6, S7.

ECM, extracellular matrix; ECV, extracellular volume; EF, ejection fraction; LAEDV, left atrial end diastolic volume; LAEF, left atrial ejection fraction; LVEDV, left ventricular end diastolic volume; LVESV, left ventricular end systolic volume; LVM, left ventricular mass; PCr/ATP, myocardial phosphocreatine/adenosine triphosphate; SV, stroke volume.

Left atrial size and function

There was a significant improvement in total left atrial strain using CMR-FT ($20.0 \pm 3.9^{\circ}$ vs $21.5 \pm 5.0^{\circ}$, $p=0.04$) and speckle-tracking echocardiography ($22.5 \pm 8.9^{\circ} \pm 26.4 \pm 8.5^{\circ}$, $p=0.03$). There was a corresponding trend towards improved left atrial ejection fraction ($41.3\% \pm 8.3\%$ vs $45.4 \pm 12.2\%$, $p=0.06$) and reservoir expansion index (0.73 ± 0.22 vs 0.94 ± 0.54 , $p=0.09$). Minimal LA volume significantly decreased ($75.8 \pm 43.6 \text{ mL}$ vs $65.9 \pm 40.8 \text{ mL}$, $p=0.04$), with a trend towards reduced maximal volume ($124.3 \pm 51.3 \text{ mL}$ vs $114.6 \pm 47.3 \text{ mL}$, $p=0.18$). No significant change in left atrial strain was observed in the control group ($20.5 \pm 7.3^{\circ}$ vs 18.9 ± 5.9 , $p=0.22$).

Myocardial energetics

A typical ^{31}P -CMR spectrum is shown in online supplemental figure 4 of the supplementary data. Mean Cramer Rao lower bounds (CRLB) for the whole group were 5.1% for PCr and 8.5% for ATP, representing satisfactory signal-to-noise ratio (SNR).^{13 14} One patient in both groups had CRLB greater than 20% (previously reported to represent unacceptable SNR)^{13 14} and was excluded. All remaining patients had CRLBs less than 20%. No significant difference in PCr/ATP ratio was found between those in New York Heart Association class I and II (1.3 ± 0.43 vs 1.1 ± 0.38 , $p=0.29$) at baseline. There was a small non-significant increase in mean PCr/ATP ratio with trientine therapy (1.27 ± 0.44 vs 1.4 ± 0.39 , $p=0.46$).

Exercise tolerance

No significant change in exercise time, VO₂ max or AT was observed (see online supplemental table S4 in the supplementary data). Target RER was not met by all participants during their examinations, however, there was no significant improvement seen in the effort-independent variables assessed.

DISCUSSION

In this open label pilot study, we found trientine to be safe and highly promising as a potential disease-modifying treatment for HCM.

LVH, myocardial fibrosis and impaired myocardial energetics are key pathophysiological features of HCM. There are currently no licensed therapies that target these disease processes in HCM, and, consequently, there are no pharmacological strategies that alter the natural history of HCM or reduce the associated risk of sudden death. Recently, the Explorer-HCM trial¹⁵ investigated the effects of a first-in class myosin inhibitor, mavacamten, in patients with symptomatic obstructive HCM. This trial demonstrated that treatment with mavacamten resulted in improved exercise capacity, left ventricular outflow tract (LVOT) gradients and functional class as well as subsequently demonstrating LM mass regression in a selected substudy.

In this current study, trientine was observed to target key HCM disease manifestations. Short-term treatment with trientine was associated with a strong trend towards LVM regression. In comparison to an observational control group, it was associated with a significant reduction in LVM. The LVH regression was primarily driven by regression of myocardial fibrosis, assessed using CMR T1 and ECV, a central driver of morbidity and mortality in HCM. Trientine was also associated with a non-significant 10% improvement in myocardial energetics. Perhaps as a consequence of modifying the LVH, myocardial fibrosis and energetics, trientine was associated with an improvement in atrial and longitudinal LV function. Furthermore, it can be postulated that the improvement in afterload-dependant measures such as LVH and LV strain

may have contributed to the observed trend in improved diastolic BP.

Copper is an essential trace element found in all body tissues and has an important role in multiple biological functions, including signalling pathways, cellular respiration and as a cofactor for enzymatic activity.³ Within the human body, copper is found in its reduced state, Cu^+ and its oxidised state, Cu^{2+} . Cu^{2+} ions are the most highly redox-active metal ions in mammals, and as such are powerful catalysts of reactive oxygen species (ROS) and oxidative stress.⁴ Excess tissue Cu^{2+} ions lead to tissue damage by catalysing the formation of damaging hydroxyl ($\text{OH}\cdot$) radicals via the Fenton reaction.³ Furthermore, Cu^{2+} ions activate the transforming growth factor (TGF)-beta1 signalling pathway, inhibit enzymatic antioxidants such as extracellular superoxide dismutase and augment the cardiotoxic effects of catecholamines.¹⁶ Experimentally, ROS are associated with myocardial hypertrophy, injury, apoptosis, necrosis and fibrosis.^{17 18} Furthermore, increased oxidative stress occurs in various models of LV pressure load and potentially perpetuates LVH,^{18–20} whereby cyclic strain causes an amplitude-related increase in ROS, associated with differential activation of kinases and induction of hypertrophic and apoptotic phenotypes.²¹

Recent research has highlighted the potential role of oxidative stress and low-grade inflammation in HCM pathophysiology.²² Dimitrow *et al.* found serum levels of 8-iso-prostaglandin F₂ α (8-iso-PGF₂ α), a biomarker of generalised cellular oxidative stress, were elevated in 54 patients with HCM compared with matched controls.²³ Patients with LVOT obstruction displayed higher 8-iso-PGF₂ α levels than those without LVOT obstruction. In a preclinical HCM study, N-acetylcysteine restored oxidised to total glutathione ratio, normalised levels of glutathiolated cardiac alpha-actin, restored myocardial levels of active protein kinase G and dephosphorylated nuclear factor of activated T cells 1 and phospho-p38, reversed cardiac and myocyte hypertrophy and interstitial fibrosis, reduced the propensity for ventricular arrhythmias and prevented cardiac dysfunction,²⁴ although a recent clinical trial of N-acetylcysteine in HCM was disappointing, although with a small sample size.²⁵ In a transgenic model of human HCM, Senthil *et al* found atorvastatin reduced LVM, wall thickness, myocyte size, myocardial levels of molecular markers of hypertrophy, lipid peroxides and oxidised mitochondrial DNA.²⁶

Accumulating data demonstrates a copper-overload state in diabetes and various forms of primary and secondary cardiomyopathies.^{6 7} Most recently, we demonstrated such a copper excess state to be present in HCM.⁹ Trientine has a range of actions thought to result from its removal of Cu^{2+} from tissue. We have demonstrated previously that trientine can reverse diabetes-induced damage to mitochondrial ultrastructure and normalise myocardial expression and enzymatic activity of proteins involved with energy metabolism, components of the mitochondrial respiratory chain and enzymes involved in

fatty acid oxidation.²⁷ This is relevant to HCM because energy depletion is hypothesised to be a primary disease mechanism, and inherited defects in mitochondrial energy production and fatty acid oxidation lead to phenotypes mimicking HCM.

Remarkably, we have demonstrated that trientine can prevent myocardial damage and result in tissue regeneration in the diabetes-damaged heart and kidney, including improvement in cardiomyocyte structure, myocardial collagen regression, LV function and alleviation of heart failure.^{8 10 28} We have also shown that trientine normalises extracellular superoxide dismutase, which inhibits ROS-mediated TGF- β activation and reverses myocardial fibrosis. Importantly, when Cu^{2+} is removed from the body bound to trientine, it does not catalyse the Fenton reaction and so it does not cause tissue damage. The topic of Cu^{2+} selective chelation therapy for systemic diseases has been reviewed in greater detail elsewhere.²⁹

Most relevant, in a randomised placebo-controlled trial in patients with type II diabetes and abnormal diastolic function, we previously demonstrated that trientine 1200 mg/day was associated with a significant reduction in LVM. Cumulative urinary copper excretion independently associated with decrease in LVM.¹⁰ The current study replicates these results in patients with HCM. Taken together with the findings of our previous work and that of others, the beneficial effects of trientine on HCM pathophysiology observed in the current study may be mediated by an antioxidant effect of chelating myocardial Cu^{2+} , leading to improved mitochondrial function and energy metabolism, and inhibition of TGF- β and profibrotic pathways. It is conceivable that by additionally targeting the accelerated fibrosis pathway in this disease, trientine may specifically address the progression of arrhythmic risk.

Limitations

This was an open-label pilot study and, thus, by its nature, was limited by its small sample size, limited duration and lack of a randomised placebo controlled parallel arm. Our patients were included on the basis of a clinical, not necessarily genetic, diagnosis. This represents a significant limitation to the study, however, it is important to note that currently, only approximately 60% of patient with clinical HCM have a confirmatory genetic mutation.³⁰ It was necessary to conduct a proof of concept study in HCM before a definitive efficacy and mechanism evaluation could take place. In light of the findings of our prior study of trientine in type II diabetes, in which LVM regression continued to increase over the 12-month study period, it is not unreasonable to extrapolate that our 6-month study period was simply too short to elicit the full potential effect of trientine on the myocardium. These shortcomings are being addressed in TEMPEST (NCT04706429; www.tempest-trial.org.uk) an NIHR-EME (ref NIHR127575) sponsored appropriately powered randomised, double-blind, placebo-controlled phase 2b multicentre trial currently under way.

While the immediate test–retest variability of our ^{31}P -CMRS method was good (intraclass correlation coefficient 0.932 in healthy volunteers), the 6-month test–retest variability was simply too high (intraclass correlation coefficient 0.429) to permit reliable detection of trientine-induced changes with our sample size.

CONCLUSION

In this small open-label pilot study in HCM, trientine was found to be safe and well tolerated. Treatment was associated with improvements in many pathophysiological features of HCM most importantly LVM. Indeed, an appropriately powered phase 2b double blinded, randomised multicentre study is now under way to answer whether trientine can slow or even halt HCM disease progression.

Contributors Study concept and design: MS, SR, CM, GC, AR, RP. Acquisition analysis or interpretation of data: all authors. Drafting, review and editing of manuscript: all authors. Study guarantor: MS.

Funding The study was funded by a MRC Confidence in Concept award. The investigational medicinal product was gifted by Univar. Univar had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, or approval of the manuscript; and decision to submit the manuscript for publication.

Competing interests Dr CM has received research support from Roche and Guerbet, served on an advisory board for Novartis and serves as an advisor for HAYA therapeutics.

Patient consent for publication Not applicable.

Ethics approval The study was approved by an ethics committee of the U.K. National Research Ethics Service (ref: 14/NW/1015) and the Medicines and Healthcare Products Regulatory Agency (21463/0220/001-0001) and performed in accordance with the Declaration of Helsinki.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

John Peter Farrant <http://orcid.org/0000-0002-9241-2410>

REFERENCES

- Watkins H, Ashrafian H, McKenna WJ. The genetics of hypertrophic cardiomyopathy: Teare redux. *Heart* 2008;94:1264–8.
- Force T, Bonow RO, Houser SR, et al. Research priorities in hypertrophic cardiomyopathy: report of a working group of the National heart, lung, and blood Institute. *Circulation* 2010;122:1130–3.
- Uriu-Adams JY, Keen CL. Copper, oxidative stress, and human health. *Mol Aspects Med* 2005;26:268–98.
- Zhang L, Ward M-L, Phillips ARJ, et al. Protection of the heart by treatment with a divalent-copper-selective chelator reveals a novel mechanism underlying cardiomyopathy in diabetic rats. *Cardiovasc Diabetol* 2013;12:123.
- Burguera JL, Burguera M, Alarcón OM, et al. Concentration changes of zinc, copper and iron in serum of chronic chagasic myocardial patients. *J Trace Elem Electrolytes Health Dis* 1988;2:215–9.
- Hlubocká Z, Marecek Z, Linhart A, et al. Cardiac involvement in Wilson disease. *J Inherit Metab Dis* 2002;25:269–77.
- Topuzoglu G, Erbay AR, Karul AB, et al. Concentrations of copper, zinc, and magnesium in sera from patients with idiopathic dilated cardiomyopathy. *Biol Trace Elem Res* 2003;95:11–18.
- Cooper GJS, Phillips ARJ, Choong SY, et al. Regeneration of the heart in diabetes by selective copper chelation. *Diabetes* 2004;53:2501–8.
- Potluri R, Roberts N, Miller C, et al. Impaired copper homeostasis in patients with hypertrophic cardiomyopathy. *Eur Heart J* 2012;33:741.
- Cooper GJS, Young AA, Gamble GD, et al. A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study. *Diabetologia* 2009;52:715–22.
- Flett AS, Hayward MP, Ashworth MT, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. *Circulation* 2010;122:138–44.
- Conway MA, Bottomley PA, Ouwkerk R, et al. Mitral regurgitation: impaired systolic function, eccentric hypertrophy, and increased severity are linked to lower phosphocreatine/ATP ratios in humans. *Circulation* 1998;97:1716–23.
- Shivu GN, Abozguia K, Phan TT, et al. ^{31}P magnetic resonance spectroscopy to measure in vivo cardiac energetics in normal myocardium and hypertrophic cardiomyopathy: Experiences at 3T. *Eur J Radiol* 2010;73:255–9.
- Abozguia K, Elliott P, McKenna W, et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. *Circulation* 2010;122:1562–9.
- Olivetto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2020;396:759–69.
- Remião F, Carmo H, Carvalho F, et al. Copper enhances isoproterenol toxicity in isolated rat cardiomyocytes: effects on oxidative stress. *Cardiovasc Toxicol* 2001;1:195–204.
- Minuz P, Fava C, Lechi A. Isoprostanol and vascular damage. *Pharmacological Reports* 2006;58:57–68.
- Sawyer DB, Siwik DA, Xiao L, et al. Role of oxidative stress in myocardial hypertrophy and failure. *J Mol Cell Cardiol* 2002;34:379–88.
- Henderson BC, Tyagi N, Ovechkin A, et al. Oxidative remodeling in pressure overload induced chronic heart failure. *Eur J Heart Fail* 2007;9:450–7.
- Jacob MHVM, Pontes MRN, Araújo ASR, et al. Aortic-banding induces myocardial oxidative stress and changes in concentration and activity of antioxidants in male Wistar rats. *Life Sci* 2006;79:2187–93.
- Pimentel DR, Amin JK, Xiao L, et al. Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. *Circ Res* 2001;89:453–60.
- Teekakirikul P, Eminaga S, Toka O, et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires TGF- β . *J Clin Invest* 2010;120:3520–9.
- Dimitrow PP, Undas A, Wolkow P, et al. Enhanced oxidative stress in hypertrophic cardiomyopathy. *Pharmacol Rep* 2009;61:491–5.
- Lombardi R, Rodriguez G, Chen SN, et al. Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. *Circulation* 2009;119:1398–407.
- Marian AJ, Tan Y, Li L, et al. Hypertrophy regression with N-acetylcysteine in hypertrophic cardiomyopathy (HALT-HCM): a randomized, placebo-controlled, double-blind pilot study. *Circ Res* 2018;122:1109–18.
- Senthil V, Chen SN, Tsybouleva N, et al. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. *Circ Res* 2005;97:285–92.
- Jüllig M, Chen X, Hickey AJ, et al. Reversal of diabetes-evoked changes in mitochondrial protein expression of cardiac left ventricle by treatment with a copper(II)-selective chelator. *Proteomics Clin Appl* 2007;1:387–99.
- Gong D, Lu J, Chen X, et al. A copper(II)-selective chelator ameliorates diabetes-evoked renal fibrosis and albuminuria, and suppresses pathogenic TGF- β activation in the kidneys of rats used as a model of diabetes. *Diabetologia* 2008;51:1741–51.
- Cooper GJS. Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease. *Drugs* 2011;71:1281–320.
- Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. *Circ Res* 2017;121:749–70.

SUPPLEMENTARY DATA

Table Titles

Table S1: Exclusion Criteria

Table S2: Patient Characteristics

Table S3: Adverse effects leading to non-completion of study

Table S4: Summary of important risks

Table S5: Laboratory and haemodynamic data at baseline and after 6 months of treatment with trientine

Table S6: Echocardiographic data at baseline and after 6 months of treatment with trientine

Table S7: Cardiac MRI at baseline and after 6 months of treatment with trientine.

Figure Titles and Legends

Figure 1: Study Flow Chart

Figure 2: Case – control comparison in change in LV mass

Figure 3: Change in Extracellular Volume Fraction

Figure 4: Voxel placement in ^{31}P -CMRS with typical ^{31}P -CMR spectrum (2,3-DPG = 2,3-diphosphoglycerate, PDE = phosphodiesterase, PCr = phosphocreatine, ATP = adenosine triphosphate). PCR/ATP ratio was calculated as the ratio of amplitudes of the PCr and α -ATP peaks.

Table S1: Exclusion Criteria

- History of any other cardiovascular disorder
- NYHA Class III / IV heart failure
- Diabetes Mellitus
- Contraindication to magnetic resonance imaging (MRI) scanning (including claustrophobia)
- Known hypersensitivity to Trientine or excipients
- Known hypersensitivity to Gadolinium-based contrast agent
- eGFR < 50ml/min/1.73m²
- BMI > 40kg/m²
- History of significant malabsorption
- Copper deficiency at baseline
- Iron deficiency at baseline
- Haemoglobin < 10g/dL
- Unresolved haematological disorder
- Severe hepatic impairment
- Untreated thyroid disease
- Autoimmune disorders/connective tissue disease
- Drug or alcohol abuse
- Pregnancy/breast-feeding. Women of childbearing potential (not >2 years post- menopausal and/or not surgically sterilised) must have a negative blood serum pregnancy test, performed at visit 1 prior to administration of study medication
- Any clinically significant or unstable medical or psychiatric condition that would interfere with the patient's ability to participate in the study
- Any other condition, which in the opinion of the research team, may put participants at risk during the study, or which may affect the outcome of the study
- New medication within the preceding month of the study (excluding short term prescriptions)
- Participation in another study involving an investigational product in the previous 12 weeks

Table S2: Patient Characteristics

	Intervention Group	Control Group	p-value
Age (years)	55.5 ± 8.4	54.7 ± 13.3	0.86
Male	15	7	
Body surface area (m ²)	2.06 ± 0.25	1.94 ± 0.24	0.24
Systolic blood pressure (mmHg)	130 ± 15	137 ± 13	0.24
Diastolic blood Pressure (mmHg)	81 ± 12	75 ± 15	0.28
Heart Rate	66.5 ± 16.3	65.1 ± 11.5	0.81
ACEi / ARB	1	2	
Beta-blockers	10	5	
Calcium Channel Blockers	1	0	
Spironolactone	0	0	
PCr/ATP ratio	1.27 ± 0.44	1.51 ± 0.82	0.36
NYHA I	14	7	
NYHA II	6	3	
EF (%)	69.0 ± 6.8	69.8 ± 8.3	0.79
Mass/BSA (g/m ²)	73.5 ± 20.0	79.8 ± 18.6	0.43

Table S3: Adverse effects leading to non-completion of study

	Gender	Length of Treatment (weeks)	Adverse Effect
1	Male	1	Abdominal bloating
2	Male	21	Oesophageal ulcer*
3	Male	20	Arthralgia [†]
4	Male	4	Migraine [†]

* Related to tablet impaction- the patient was taking multiple other prescribed and over the counter medications, and the investigational medicinal product (IMP) was not deemed the culprit at OGD.

[†] Pre-existing prior to study

Table S4: Summary of important risks

Adverse Event	Number of patients experiencing adverse event (Total number of patients = 20)
Gastric complaints (nausea, gastric pain, bloating, diarrhoea, dyspepsia)	5
Dizziness	2
Increased exercise capacity	2
Chest infection	3
Increased Urinary Frequency	1
Leukopenia	1
Vivid dreams	1
Appendicitis*	1
Headache	2
Influenza-like illness	1
Common Cold	1
Vivid dreams	1
Palpitations requiring admission*	1
Wrist Sprain*	1
Adhesive capsulitis of the shoulder	1

*Serious adverse event

Table S5: Laboratory and haemodynamic data at baseline and after 6 months of treatment with trientine

	Baseline	Follow-up	p-value
<i>Laboratory data</i>			
Haemoglobin (g/l)	145.5 ± 13.3	143.2 ± 12.5	0.40
Urea (mmol/l)	5.1 ± 1.0	4.9 ± 1.2	0.25
Creatinine (µmol/l)	75.0 ± 13.0	74.2 ± 11.7	0.71
eGFR (ml/min/1.73m ²)	82.7 ± 8.6	84.5 ± 7.2	0.30
Alk. Phos (iu/l)	73.0 ± 19.8	78.6 ± 19.1	0.03
ALT (iu/l)	20.5 ± 6.4	23.6 ± 5.0	0.07
Magnesium (mmol/l)	0.87 ± 0.08	0.81 ± 0.12	0.14
Serum Copper (µmol/l)	16.5 ± 2.3	16.6 ± 2.7	0.83
Serum Caeruloplasmin (g/l)	0.23 ± 0.03	0.24 ± 0.03	0.04
Serum Zinc (µmol/l)	20.4 ± 5.4	25.3 ± 7.9	0.15
<i>Haemodynamics</i>			
Systolic BP (mmHg)	131 ± 15	125 ± 15	0.21
Diastolic BP (mmHg)	83 ± 14	74 ± 7	0.06
Heart Rate (bpm)	57.5 ± 10.0	58.8 ± 9.2	0.59
BSA (m ²)	2.07 ± 0.28	2.06 ± 0.28	0.43
<i>Cardiopulmonary Exercise Testing</i>			
Exercise time (min)	14.7 ± 3.2	14.4 ± 2.9	0.26
Anaerobic Threshold (l/mn)	1.41 ± 0.46	1.47 ± 0.36	0.89
VO ₂ Max (l/mn)	2.44 ± 0.81	2.41 ± 0.74	0.46
PR interval (ms)	184 ± 20	182 ± 19	0.42
QRS duration (ms)	110 ± 12	109 ± 13	0.44
QTc (ms)	432 ± 27	429 ± 20	0.75

Table S6: Echocardiographic data at baseline and after 6 months of treatment with trientine

	Baseline	Follow-up	p-value
E velocity (cm/s)	60.8 ± 16.7	61.8 ± 12.9	0.67
A velocity (cm/s)	64.4 ± 23.0	63.7 ± 20.3	0.77
E/A ratio	1.11 ± 0.67	1.10 ± 0.50	0.84
Mean S' Velocity (cm/s)	6.9 ± 2.5	8.1 ± 1.9	0.03
Mean E' Velocity (cm/s)	6.8 ± 3.4	7.0 ± 2.5	0.71
Mean A' Velocity (cm/s)	7.4 ± 3.1	8.4 ± 2.7	0.11
Mean E/E'	10.7 ± 3.3	10.1 ± 3.2	0.43
Mitral Decel. Time (ms)	295 ± 79	265 ± 47	0.11

Table S7: Cardiac MRI at baseline and after 6 months of treatment with trientine.

	Baseline	Follow-up	p-value
<i>Cardiac MRI: Left ventricle</i>			
LVEDV (ml)	171 ± 36	169 ± 38	0.57
LVESV (ml)	54 ± 20	52 ± 20	0.41
SV (ml)	117 ± 22	117 ± 23	0.98
EF (%)	69 ± 7	70 ± 6	0.55
LVM (g)	152 ± 54	147 ± 55	0.06
LVEDVi (ml/m ²)	84 ± 10	84 ± 12	0.84
LVESVi (ml/m ²)	26 ± 7	26 ± 8	0.62
SVi (ml/m ²)	58 ± 9	59 ± 8	0.75
LVMi (g/m ²)	73 ± 20	73 ± 22	0.48
Native septal T1 (ms)	1060 ± 47	1049 ± 42	0.06
ECV Fraction (%)	30.0 ± 4.5	29.5 ± 4.0	0.06
Total Myocardial Volume (ml)	145 ± 52	140 ± 53	0.05
ECM Volume (ml)	44 ± 18	42 ± 17	0.04
Cellular Volume (ml)	101 ± 36	99 ± 37	0.11
GLS	-18.3 ± 3.4	-19.4 ± 3.4	0.03
PCr / ATP Ratio	1.27 ± 0.44	1.4 ± 0.39	0.46
<i>Cardiac MRI: Left atrium</i>			
LAESV (ml)	75.8 ± 43.6	65.8 ± 40.9	0.04
LAEDV (ml)	124.4 ± 51.3	114.6 ± 47.3	0.18
Pre-atrial contraction vol (ml)	102.9 ± 46.7	93.3 ± 40.1	0.08
LAESVi (ml/m ²)	37.3 ± 17.9	32.6 ± 17.4	0.06
LAEDVi (ml/m ²)	61.7 ± 21.9	57.4 ± 20.8	0.25
Pre-atrial contraction vol i (ml/m ²)	50.9 ± 19.8	46.6 ± 17.2	0.12
Total EF (%)	41.3 ± 8.3	45.5 ± 12.2	0.07
Passive EF (%)	18.0 ± 5.8	18.7 ± 4.9	0.64
Booster EF (%)	28.4 ± 8.9	33.2 ± 13.6	0.16
LA Expansion Index	0.73 ± 0.22	0.94 ± 0.54	0.09
Total strain (%)	20.0 ± 3.9	21.5 ± 5.0	0.04
Peak systolic strain rate (-1)	0.75 ± 13	0.83 ± 0.19	0.11
Passive Strain (%)	9.47 ± 3.06	11.1 ± 5.60	0.68
Peak early negative strain rate (-1)	-0.50 ± 0.29	-0.49 ± 0.23	0.56
Active Strain (%)	10.53 ± 3.08	10.41 ± 4.20	0.76
Peak late negative strain rate (-1)	-0.68 ± 0.20	-0.66 ± 0.30	0.91

ECV fraction was calculated as $ECV = (1 - \text{hematocrit}) \times \lambda$, where λ is the partition coefficient. Total myocardial volume was $LV \text{ Mass} / 1.05$. The total extracellular volume (ECM) was calculated with the formula $ECM = ECV \times LVM / 1.05$, while the cellular volume was calculated as $\text{Cellular volume (ml)} = \text{Total myocardial volume} - \text{ECM volume}$.

Figure 1





Figure 2

Figure 3




Figure 4

